LC
PLRX icon

Lindbrook Capital’s Pliant Therapeutics PLRX Stock Holding History

Lindbrook Capital’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25
Closed -$329 – 2901
2024
Q4 		$329 Buy
25
+11
+79% +$150 ﹤0.01% 2685
2024
Q3 		$157 Sell
14
-123
-90% -$1.54K ﹤0.01% 2774
2024
Q2 		$1.47K Buy
+137
New +$1.77K ﹤0.01% 2421
2024
Q1 		– Sell
-50
Closed -$906 – 2735
2023
Q4 		$906 Sell
50
-17
-25% -$259 ﹤0.01% 2486
2023
Q3 		$1.16K Buy
+67
New +$1.16K ﹤0.01% 2312
2022
Q2 		– Sell
-224
Closed -$2K – 2704
2022
Q1 		$2K Buy
+224
New +$2.29K ﹤0.01% 2053
2021
Q4 		– Sell
-700
Closed -$12K – 2180
2021
Q3 		$12K Buy
+700
New +$14.9K ﹤0.01% 926

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Lindbrook Capital's PLRX Position: Q1 2025 in Review

Lindbrook Capital sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 25 shares — an estimated $329 sold.

Lindbrook Capital first reported a position in PLRX in Q3 2021 and held it in 7 quarters. The position peaked at $12K in Q3 2021. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Lindbrook Capital reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 25 Pliant Therapeutics shares in Q1 2025, an estimated $329.
  • Lindbrook Capital first reported a position in Pliant Therapeutics in Q3 2021 and held it in 7 quarters.
  • Lindbrook Capital's Pliant Therapeutics position peaked at $12K in Q3 2021.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.